Cambridge, United States
SURGE Therapeutics, founded in 2016, is making waves in the Biotechnology, Health Care, and Life Sciences sectors with their pioneering focus on intraoperative immunotherapy.
The company's slogan, "The intraoperative immunotherapy company," highlights their commitment to improving cancer patient survival rates by altering the deployment of cancer immunotherapy. Their approach aims to concentrate the effective dose precisely where and when it's most needed, particularly during surgery, which remains the standard treatment for solid tumors.
Headquartered in the United States, SURGE Therapeutics recently closed a $32.00M Series B funding round on July 19, 2023. This round was backed by notable investors including Khosla Ventures, Pitango Venture Capital, DHVC, and others. The involvement of these prominent names reflects confidence in the company's disruptive potential to prevent post-surgical cancer recurrences and significantly enhance patient outcomes.
